• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20058 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     Agency for Care Effectiveness (ACE) Somatropin for the treatment of growth failure in children
2017     Agency for Care Effectiveness (ACE) Gemcitabine for the treatment of cancer
2017     Agency for Care Effectiveness (ACE) Sumatriptan for the treatment of acute migraine attacks
2017     Agency for Care Effectiveness (ACE) Temozolomide for the treatment of malignant glioma
2017     Agency for Care Effectiveness (ACE) Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2020     Agency for Care Effectiveness (ACE) Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Agency for Care Effectiveness (ACE) Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2020     Agency for Care Effectiveness (ACE) Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2019     Agency for Care Effectiveness (ACE) Febuxostat for treating chronic hyperuricaemia in adults with gout
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2019     Agency for Care Effectiveness (ACE) Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019     Agency for Care Effectiveness (ACE) Oral COX-2 inhibitors for treating pain
2019     Agency for Care Effectiveness (ACE) Ferric carboxymaltose for treating iron deficiency anaemia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating cervical dystonia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019     Agency for Care Effectiveness (ACE) Endothelin receptor antagonists for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020     Agency for Care Effectiveness (ACE) Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020     Agency for Care Effectiveness (ACE) Epoprostenol for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Vonoprazan for treating helicobacter pylori infection
2020     Agency for Care Effectiveness (ACE) Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2020     Agency for Care Effectiveness (ACE) Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020     Agency for Care Effectiveness (ACE) Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020     Agency for Care Effectiveness (ACE) Mycophenolate mofetil for immunosuppression
2020     Agency for Care Effectiveness (ACE) Adalimumab for treating inflammatory conditions
2020     Agency for Care Effectiveness (ACE) Abiraterone for treating metastatic prostate cancer
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2021     Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021     Agency for Care Effectiveness (ACE) Metformin extended release for treating type 2 diabetes mellitus
2021     Agency for Care Effectiveness (ACE) Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active psoriatic arthritis
2021     Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2009     Agency for Health Technology Assessment in Poland (AHTAPol) Clinical effectiveness analysis of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension: a systematic review of randomised controlled trials
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Treatment of pulmonary arterial hypertension in Poland - current practice. Survey results
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Cost-effectiveness analysis of PET-CT positron emission tomography and the diagnostic technologies financed from public sources in oncological diagnostics in Poland
2005     Agency for Healthcare Research and Quality (AHRQ) Effects of omega-3 fatty acids on cancer
2006     Agency for Healthcare Research and Quality (AHRQ) Comparative effectiveness and safety of analgesics for osteoarthritis